$3.72
Today
as of Sep 4, 16:54 ET
Last 30 days
Recent Press Releases & News
SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics Q2 Earnings Call Highlights
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...
Overview
52-week range
$1.85
$5.15
57% of range
Avg surprise (last 3)
-21.3%
Avg reaction (last 2)
+0.7%
50% positive
Latest IV / EM
90%
EM ±14.1% · $4 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.28 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-0.35 | $-0.20 | -75.0% | +37.5% | -2.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.21 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-1.09 | $-0.82 | -32.9% | — | — | earnings |
| Fri May 9, 2025 | Mar/2025 | $-0.56 | $1.00 | +44.0% | — | +4.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.12 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.79 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.54 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.97 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.36 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-1.46 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-23M | $-20M | — | $-13M | $-10M | $-11M | — | $-11M |
| Net income | $-22M | $-19M | — | $45M | $-10M | $-5M | — | $-10M |
| EPS (diluted) | $-0.28 | $-0.35 | — | $-0.21 | $-1.09 | $-0.56 | — | $-1.12 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8M | $21M | $11M | $29M | $4M | $6M | $9M | $9M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $108M | $113M | $101M | $113M | $9M | $16M | $24M | $33M |
| Total assets | $238M | $248M | $173M | $183M | $30M | $38M | $44M | $54M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $23M | $21M | $21M | $18M | $18M | $17M | $18M | $17M |
| Total equity | $215M | $227M | $151M | $165M | $12M | $21M | $26M | $37M |